FEATURED
Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
DEALS
Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
PRESS RELEASES
L.B. Bohle to Unveil Groundbreaking Innovations at Interpack
The premier trade fair for the packaging and pharmaceutical industry, Interpack, will open its doors in Düsseldorf from the 4th
EDITOR’S PICKS
Terebellum Lists Seven Specialty Pharma Trends for 2023
Terebellum, a global healthcare and specialty pharmacy solutions company, has revealed seven industry trends to watch out for in 2023.
RESOURCES
GERBU Adjuvants – Ready to Use Immunoadjuvants for Better Results
GERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
MANUFACTURING PROJECTS
Continuous Manufacturing Line for Oral Solids, WuXi STA, China
WuXi STA, a subsidiary of WuXi AppTec, opened the doors of its first pharmaceutical product Continuous Manufacturing (CM) line for
CLINICAL TRIALS
Pfizer and BioNTech Start Phase 1/2 Study of First mRNA-based Shingles Vaccine in the US
Pfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
REGULATORY
Bristol Myers Squibb’s Reblozyl® (luspatercept) Approved by EC for Anemia in Adults with NTDT
American multinational pharmaceutical company Bristol Myers Squibb announced on Friday that the European Commission (EC) has awarded the company with
SELECTED PRODUCTS
GERBU Ready-to-use Adjuvants (PluS, S, F, M, and P)
GERBU offers ready-to-use adjuvants which can dramatically improve the yield of polyclonal and monoclonal antibodies. Adjuvant auxiliary drug carrier immunoadjuvant,
